flumazenil has been researched along with Delirium of Mixed Origin in 8 studies
Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.
flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.
| Excerpt | Relevance | Reference |
|---|---|---|
| "BACKGROUND Olanzapine is an antipsychotic drug and is used in critical care to treat delirium." | 8.12 | Coma, Severe Hypotension, and Pinpoint Pupils After Olanzapine Intoxication in the Intensive Care Unit with Symptom Reversal After Administration of Flumazenil. ( Aiff, H; Guldberg, J; Gustafsson, JM; Pålsson, P, 2022) |
| " We present the case of a healthy 12-year-old girl who received preoperative midazolam with the desired anxiolytic effect, underwent a brief general anesthetic, and then exhibited postoperative delirium, consisting of a transient associative agnosia and expressive aphasia." | 7.81 | Emergence delirium with transient associative agnosia and expressive aphasia reversed by flumazenil in a pediatric patient. ( Cook-Sather, SD; DiPuppo, PM; Drobish, JK; Kelz, MB, 2015) |
| " During his ED workup, the patient experienced an acute delirium 25 min after being given 2 mg of Lorazepam." | 7.72 | Flumazenil reversal of lorazepam-induced acute delirium. ( Flanigan, J; Olshaker, JS, 2003) |
| " For patients being treated for alcohol withdrawal, flumazenil can diagnose and treat benzodiazepine delirium without precipitating serious or life-threatening adverse events." | 5.40 | Safety and efficacy of flumazenil for reversal of iatrogenic benzodiazepine-associated delirium toxicity during treatment of alcohol withdrawal, a retrospective review at one center. ( Adkins, AR; Burkhart, KK; Donovan, JW; Haggerty, DA; Hieger, MA; Moore, PW; Rasimas, JJ; Waskin, JA; Wert, Y, 2014) |
| "BACKGROUND Olanzapine is an antipsychotic drug and is used in critical care to treat delirium." | 4.12 | Coma, Severe Hypotension, and Pinpoint Pupils After Olanzapine Intoxication in the Intensive Care Unit with Symptom Reversal After Administration of Flumazenil. ( Aiff, H; Guldberg, J; Gustafsson, JM; Pålsson, P, 2022) |
| " Midazolam, a benzodiazepine commonly administered to children for anxiolysis, may precipitate paradoxical agitation and delirium, a rare but alarming effect that warrants prompt identification and treatment." | 3.81 | Successful flumazenil reversal of paradoxical reaction to midazolam in a child. ( Beck, LA; Jackson, BF; Losek, JD, 2015) |
| " We present the case of a healthy 12-year-old girl who received preoperative midazolam with the desired anxiolytic effect, underwent a brief general anesthetic, and then exhibited postoperative delirium, consisting of a transient associative agnosia and expressive aphasia." | 3.81 | Emergence delirium with transient associative agnosia and expressive aphasia reversed by flumazenil in a pediatric patient. ( Cook-Sather, SD; DiPuppo, PM; Drobish, JK; Kelz, MB, 2015) |
| " During his ED workup, the patient experienced an acute delirium 25 min after being given 2 mg of Lorazepam." | 3.72 | Flumazenil reversal of lorazepam-induced acute delirium. ( Flanigan, J; Olshaker, JS, 2003) |
| " For patients being treated for alcohol withdrawal, flumazenil can diagnose and treat benzodiazepine delirium without precipitating serious or life-threatening adverse events." | 1.40 | Safety and efficacy of flumazenil for reversal of iatrogenic benzodiazepine-associated delirium toxicity during treatment of alcohol withdrawal, a retrospective review at one center. ( Adkins, AR; Burkhart, KK; Donovan, JW; Haggerty, DA; Hieger, MA; Moore, PW; Rasimas, JJ; Waskin, JA; Wert, Y, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Pålsson, P | 3 |
| Guldberg, J | 3 |
| Gustafsson, JM | 3 |
| Aiff, H | 3 |
| Nelson, LS | 1 |
| Moore, PW | 2 |
| Donovan, JW | 2 |
| Burkhart, KK | 1 |
| Waskin, JA | 1 |
| Hieger, MA | 2 |
| Adkins, AR | 1 |
| Wert, Y | 1 |
| Haggerty, DA | 1 |
| Rasimas, JJ | 1 |
| Lucyk, S | 1 |
| von Schweinitz, BA | 1 |
| Hoffman, RS | 1 |
| Jackson, BF | 1 |
| Beck, LA | 1 |
| Losek, JD | 1 |
| Drobish, JK | 1 |
| Kelz, MB | 1 |
| DiPuppo, PM | 1 |
| Cook-Sather, SD | 1 |
| Olshaker, JS | 1 |
| Flanigan, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Flumazenil on Hypoactive Delirium in the ICU: A Double-Blind, Placebo-Controlled Pilot Study[NCT02899156] | Phase 4 | 22 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to A planned interim analysis led to the trial being stopped early based on the observed size effect and power analysis.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
average duration of time patient was randomized to each infusion up to 72 hours (NCT02899156)
Timeframe: up to 72 hours after the start of the infusion
| Intervention | hours (Mean) |
|---|---|
| Flumazenil Group | 54.8 |
| Placebo Group | 58.2 |
average maximum rate (ml/hr) during the 72 hours after study infusion (NCT02899156)
Timeframe: up to 72 hours after the start of the infusion
| Intervention | milliliters per hour (Mean) |
|---|---|
| Flumazenil Group | 5 |
| Placebo Group | 5.2 |
length of time that the patient was admitted to an intensive care unit service during the hospital stay (NCT02899156)
Timeframe: duration of admission to the intensive care unit
| Intervention | days (Mean) |
|---|---|
| Flumazenil Group | 7.8 |
| Placebo Group | 7 |
Defined by the number of days in the 14-day period after randomization that the patient was alive and not delirious (i.e. CAM-ICU negative). Zero delirium-free days will be observed for patients that die within the 14-day period. (NCT02899156)
Timeframe: up to 14 days after randomization
| Intervention | days (Median) |
|---|---|
| Flumazenil Group | 12.7 |
| Placebo Group | 9.2 |
number of days within the first 28 days after enrollment that the patient was free from needing mechanical ventilation (NCT02899156)
Timeframe: up to 28 days after randomization
| Intervention | days (Mean) |
|---|---|
| Flumazenil Group | 23.6 |
| Placebo Group | 24.9 |
defined by the proportion of patients who were delirium free at 14 days after randomization (NCT02899156)
Timeframe: up to 14 days after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Flumazenil Group | 9 |
| Placebo Group | 7 |
number of times that a RASS score of + 2 to +4 occurred that did not resolve with decreasing study infusion (NCT02899156)
Timeframe: up to 72 hours after the start of the infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Flumazenil Group | 0 |
| Placebo Group | 0 |
8 other studies available for flumazenil and Delirium of Mixed Origin
| Article | Year |
|---|---|
Coma, Severe Hypotension, and Pinpoint Pupils After Olanzapine Intoxication in the Intensive Care Unit with Symptom Reversal After Administration of Flumazenil.
Topics: Aged; Benzodiazepines; Coma; Delirium; Flumazenil; Humans; Hypotension; Intensive Care Units; Male; | 2022 |
Coma, Severe Hypotension, and Pinpoint Pupils After Olanzapine Intoxication in the Intensive Care Unit with Symptom Reversal After Administration of Flumazenil.
Topics: Aged; Benzodiazepines; Coma; Delirium; Flumazenil; Humans; Hypotension; Intensive Care Units; Male; | 2022 |
Coma, Severe Hypotension, and Pinpoint Pupils After Olanzapine Intoxication in the Intensive Care Unit with Symptom Reversal After Administration of Flumazenil.
Topics: Aged; Benzodiazepines; Coma; Delirium; Flumazenil; Humans; Hypotension; Intensive Care Units; Male; | 2022 |
Coma, Severe Hypotension, and Pinpoint Pupils After Olanzapine Intoxication in the Intensive Care Unit with Symptom Reversal After Administration of Flumazenil.
Topics: Aged; Benzodiazepines; Coma; Delirium; Flumazenil; Humans; Hypotension; Intensive Care Units; Male; | 2022 |
Alcohol withdrawal and flumazenil: not for the faint of heart.
Topics: Alcohol Deterrents; Alcohol Withdrawal Delirium; Alcohol Withdrawal Seizures; Antidotes; Delirium; D | 2014 |
Safety and efficacy of flumazenil for reversal of iatrogenic benzodiazepine-associated delirium toxicity during treatment of alcohol withdrawal, a retrospective review at one center.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Deterrents; Alcohol Withdrawal Delirium; Alcohol Withdrawal | 2014 |
In response to: safety and efficacy of flumazenil for reversal of iatrogenic benzodiazepine-associated delirium toxicity during treatment of alcohol withdrawal, a retrospective review at one center.
Topics: Alcoholism; Antidotes; Benzodiazepines; Delirium; Flumazenil; Humans; Retrospective Studies; Substan | 2014 |
The toxicologist and delirium: flumazenil as a diagnostic and therapeutic tool for delirium during the course of alcohol withdrawal.
Topics: Alcoholism; Benzodiazepines; Delirium; Flumazenil; Humans; Substance Withdrawal Syndrome | 2014 |
Successful flumazenil reversal of paradoxical reaction to midazolam in a child.
Topics: Akathisia, Drug-Induced; Anti-Anxiety Agents; Antidotes; Child, Preschool; Delirium; Female; Flumaze | 2015 |
Emergence delirium with transient associative agnosia and expressive aphasia reversed by flumazenil in a pediatric patient.
Topics: Adjuvants, Anesthesia; Agnosia; Anesthesia, General; Aphasia, Broca; Child; Delirium; Female; Flumaz | 2015 |
Flumazenil reversal of lorazepam-induced acute delirium.
Topics: Anti-Anxiety Agents; Antidotes; Delirium; Flumazenil; Humans; Lorazepam; Male; Middle Aged | 2003 |